Modified Serpins for Hemophilia Treatment via Protease Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia, such as hemophilia A and B, are hindered by the development of inhibitory antibodies, high treatment costs, and the short half-life of clotting factors, leading to frequent and unpredictable bleeding episodes and increased risk of chronic arthropathy.
Innovation Solution
Modified serpin molecules with specific mutations in the reactive center loop, particularly at positions P4, P2, P1, and P1′, are engineered to enhance their specificity for anticoagulant proteases like activated Protein C, potentially reducing bleeding episodes and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard replacement therapy with clotting factors is used, then bleeding disorders can be treated, but patients develop inhibitory antibodies rendering treatment ineffective
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of serpin molecules through site-directed mutagenesis. Specific residues in the reactive center loop (RCL) are mutated to alter protease specificity, transforming the molecule's interaction parameters with coagulation factors. This enables the serpin to selectively inhibit activated Protein C while sparing other coagulation proteases, thereby maintaining treatment efficacy without inducing inhibitory antibodies against standard clotting factors
Solution Approach 2:
The patent implements local quality changes by introducing mutations at specific positions (P4, P2, P1, P1') within the reactive center loop of the serpin molecule. Rather than altering the entire molecule, localized amino acid substitutions are made to precisely tune the specificity profile. This allows the serpin to acquire enhanced specificity for activated Protein C while preserving its overall structure and function, avoiding the development of broad-spectrum inhibitory antibodies
2Reliability
If frequent treatments are administered to overcome short half-life, then hemostatic levels can be maintained, but treatment costs increase and patient burden increases
Solution Approach 1:
The patent applies parameter changes by engineering modified serpin molecules with altered pharmacokinetic properties. Through amino acid sequence optimization and structural modifications, the half-life of the therapeutic molecule is extended. This reduces the frequency of administrations needed to maintain effective plasma concentrations, thereby reducing treatment burden and associated costs while maintaining reliable hemostatic protection
3Reliability
If bypassing agents are used to treat patients with inhibitors, then bleeding can be controlled, but treatment is expensive and response is variable
Solution Approach 1:
The patent implements local quality changes by introducing targeted mutations at specific positions (P4, P2, P1, P1') within the reactive center loop of the serpin molecule. Rather than altering the entire molecule, localized amino acid substitutions are made to precisely tune the specificity profile. This allows the serpin to acquire enhanced specificity for activated Protein C while preserving its overall structure and function
Solution Approach 2:
The patent applies parameter changes by modifying the amino acid sequence of serpin molecules through site-directed mutagenesis. Specific residues in the reactive center loop (RCL) are mutated to alter protease specificity, transforming the molecule's interaction parameters with coagulation factors. This enables the serpin to selectively inhibit activated Protein C while sparing other coagulation proteases
Data Source
AI summary
This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1′ residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.